Collaborating Investigator: Wayne Rowe Affiliation: Sanofi Funding Status: InternalProject Period: 05/2023-04/2025 Summary The goal of SP #11 is to expand human and murine NK cells on hydrogel-based MP platforms. Human NK cells have been notoriously difficult to expand. We will provide various hydrogel-based MP platforms to stimulate human NK cells for these...
Collaborating Investigator: Christopher JewellAffiliation: University of Maryland College Park Funding Status: NIH R01AI169686Project Period: 02/01/22-01/31/27 Summary The goal of SP #9 is to understand and control the integration of signals in the lymph node (LN) microenvironment to enable potent, myelin-specific immunotherapies that avoid immunosuppression. This will be approached using a platform that combines direct intra-LN (i.LN.)...
Collaborating Investigator: Wenhui HuAffiliation: Temple University Funding Status: NIH R01AI174301Project Period: 12/01/22-02/28/27 Summary The goal of SP #7 is intracellular delivery of mRNA and CRISPR/Cas genome editors for HIV treatment. This requires a delivery system for CD4+ T cell targeting and efficient intracellular delivery. NIMs developed in TR&D2 Aim 3 for gene delivery to T cells will be used to overcome this delivery...
Collaborating Investigator: Raffaella TosoAffiliation: Spark Therapeutics Funding Status: InternalProject Period: 01/19/19-12/31/25 Summary The goal of SP #6 is to use non-viral nanoparticle delivery vehicles for gene transfer to the retina. Spark Therapeutics is a leader in ocular gene therapy, including an FDA-approved ocular viral gene therapy commercial product, and is interested in also investigating alternative carriers that could have...